Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Protein kinase inhibitor Stories

2011-10-31 10:22:31

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs. The...

2011-10-25 07:00:00

SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program. "Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well...

2011-10-12 07:00:00

SAN FRANCISCO, Oct. 12, 2011 /PRNewswire/ -- Today Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and Bayer HealthCare restructured their partnership for the global development and marketing of Nexavar® (sorafenib) tablets and entered into a new agreement related to regorafenib, a late-stage oncology compound. Under the terms of the agreements, regorafenib is a Bayer compound, and Bayer will have the final decision-making authority for global development and...

2011-10-10 19:35:28

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers – combine them with inhibitors of the MEK/ERK signaling pathway. In...

2011-09-27 08:30:00

STOCKHOLM, Sept. 27, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from an exploratory clinical trial evaluating its investigational compound BIBF 1120 in patients with metastatic colorectal cancer (mCRC). In this Phase I/II study of 126 patients comparing BIBF 1120 as first-line treatment to bevacizumab, both in combination with mFOLFOX6 (6th modified regimen of folinic acid [leucovorin], fluorouracil, and oxaliplatin), the...

2011-09-06 08:00:00

RIDGEFIELD, Conn., Sept. 6, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. recently announced the initiation of two global phase II studies evaluating afatinib (BIBW 2992) in patients with inflammatory and metastatic breast cancer who have an overexpression of the erbB2 (human epidermal receptor 2 or HER2) protein, also known as HER2-positive patients. Afatinib is an investigational orally-administered irreversible inhibitor of the erbB family of receptor tyrosine...

2011-08-18 03:00:00

LUXEMBOURG, August 18, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announced today the expansion of its senior management team with the appointment of three experienced international pharma executives. Alex Leech joins as Vice President, Head of Finance and Operations, James Sandy as Senior Vice President, Head of Development, and Peter Spargo as Senior Vice President for...

2011-08-09 22:18:00

SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the signing of a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765, a first-in-class, small molecule inhibitor of Bruton's tyrosine kinase (Btk) for the treatment of hematologic malignancies (blood cancers). Under the Agreement, the NCI's Division of Cancer Treatment and Diagnosis (DCTD)...

2011-08-03 07:30:00

SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the expansion of their Collaborative Research, Development and Commercialization Agreement to also include Proacta's PR610 compound, a hypoxia-activated pro-drug for the treatment of cancer. Based on compelling pre-clinical data on PR610, the parties agreed to expand their existing collaboration to include PR610. The initial agreement, signed in February 2011, for...

2011-07-01 06:54:20

(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...